Journal
EPIGENOMICS
Volume 4, Issue 3, Pages 261-268Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/EPI.12.25
Keywords
females; folate; metabolic syndrome; methylation; MTHFR; schizophrenia
Categories
Funding
- NIMH [R01 MH082784-01]
- NIH-NCCR, GCRC Program [UL1RR024986]
- Chemistry Core of the Michigan Diabetes Research and Training Center [NIH5P60 DK 20572]
- Washtenaw Community Health Organization
Ask authors/readers for more resources
Aim: In schizophrenia, metabolic syndrome incidence is double that of the general population, with women having a higher incidence. Pharmacogenetically regulated folic acid may be related to this risk. DNA methylation and metabolic syndrome within this group has not been previously studied. Methods: Metabolic syndrome was evaluated with fasting laboratory measurements, and dietary and lifestyle assessments. Methylation analysis used a peripheral sample for the LINE-1 assay. DNA was also genotyped for MTHFR 677C/T. Results: This analysis included 133 subjects. We found a significant relationship between LINE-1 methylation, and an interaction between MTHFR and gender, controlling for serum folate (p = 0.008). Females with the 677TT genotype had the lowest methylation (56%) compared with the other groups (75%). Conclusion: TT genotype females had the lowest methylation, which may explain metabolic syndrome gender differences in schizophrenia. Folate supplementation may be a suggested intervention within schizophrenia; however, additional work is required.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available